Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASTER trial in TKI-resistant chronic myeloid leukaemia
ISRCTN68270067Phase 2Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Aug 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tazemetostat, idasanutlin, imatinib, nilotinib, dasatinib and 2 more in chronic myelogenous leukemia (CML) (3 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Treatment responder rate. Started Aug 2019; status: terminated.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN68270067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68270067.